Kolexia
Roy Lydia Hématologie
Roy Lydia
Hématologie
Hôpital Henri Mondor
Créteil, France
146 Activités
64 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Leucémie myéloïde chronique BCR-ABL positive Leucémies Leucémie myéloïde Myélofibrose primitive Syndromes myéloprolifératifs Polyglobulie Polyglobulie primitive essentielle Thrombocytose Thrombocytémie essentielle

Collaborateurs

Voir plus
Etienne Gabriel
Etienne Gabriel
Institut Bergonié, Bordeaux, France
Legros Laurence
Legros Laurence
Hôpital Paul Brousse, Villejuif, France
Nicolini Franck
Nicolini Franck
Centre Léon-Bérard, Lyon, France
Ianotto Jean-Christophe
Ianotto Jean-Christophe
Hôpital Morvan, Brest, France

Industries

Voir plus
Novartis
8 collaboration(s)
Dernière en 2023
Pfizer
7 collaboration(s)
Dernière en 2023
Abbvie
4 collaboration(s)
Dernière en 2023
AMOMED PHARMA
2 collaboration(s)
Dernière en 2020

Dernières activités

Voir plus
Discontinuation of TyrosIne Kinase Inhibitors (TKI) in Chronic Myeloid Leukemia (CML) and Impact on the Immune System: Discontinuation of TyrosIne Kinase Inhibitors (ITK) in Chronic Myeloid Leukemia (LMC) and Impact on the Immune System: a Randomized Comparative Study of Two Therapeutic Strategies
Essai Clinique (CHU Poitiers)   19 mars 2024
BIO-TIMER: Value of Biological Age, in Addition to Individual Frailty, for Personalising the Management of Cancer Treated With Targeted Therapy: the Model of Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors.
Essai Clinique (CHU Clermont-Ferrand)   29 février 2024
Correction: Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib - interim results from the DAstop2 trial.
Leukemia   28 février 2024
Role of red cell mass evaluation in myeloproliferative neoplasms with splanchnic vein thrombosis and normal hemoglobin value: a study of the France Intergroupe des Syndromes myeloprolifératifs.
Haematologica   08 février 2024
Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib - interim results from the DAstop2 trial.
Leukemia   26 janvier 2024
Distinct clinico-molecular arterial and venous thrombosis scores for myeloproliferative neoplasms risk stratification.
Leukemia   27 décembre 2023
Optimizing the use of bosutinib in patients with chronic-phase chronic myeloid leukemia: Recommendations of a panel of experts from the Fi-LMC (French CML working group).
Bulletin du cancer   11 décembre 2023
Characteristics, Outcomes, Tfr Rates in Young Adults with Chronic Myeloid Leukemia in the Tyrosine Kinase Inhibitor Era: A French Observational Study
65th ASH Annual Meeting Abstracts   02 novembre 2023
Mutation of Epigenetic Regulators at Diagnosis Is an Independent Predictor of Tyrosine Kinase Inhibitor Treatment Failure: A Report from the Residiag Study
65th ASH Annual Meeting Abstracts   02 novembre 2023
T rial of Imatinib after Ponatinib Induction (TIPI) in the Front-Line Treatment of Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Setting. Report of the First Therapeutic Sequence
65th ASH Annual Meeting Abstracts   02 novembre 2023